Global Irritable Bowel Syndrome (IBS) Market Insights, 2014-2026 – 843 Million Prevalent Cases Projected by 2026

NEXT STORY
I-Mab Expands Global Out-Licensing and Business Development Efforts
PREV STORY
Altimmune Announces Financial Results for the Year Ended December 31, 2019 and Provides a Corporate Update
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

ORIC Pharmaceuticals to Present Update on CD73 Inhibitor Program in Multiple Myeloma at the American Society of Hematology (ASH) Annual Meeting

author_avatar
NASDAQ Market News

Cue Biopharma to Present at the 2021 Frontiers in Cancer Immunotherapy Conference

author_avatar
NASDAQ Market News

OV increases its share capital due to warrant exercise

author_avatar
NASDAQ Market News